Vaccines, Pneumococcal, Vaccines, Pneumococcal Conjugate Vaccine
Conditions
Keywords
pneumococcus conjugated vaccine 7 valent
Brief summary
To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.
Detailed description
This study will require 6 months to be completed (3 months for nasopharyngeal samples collection; 3 months dor analysis). Each child will participate for a 1 day period.
Interventions
BIOLOGICALpneumococcus conjugate vaccine 7 valent to reduce carriage
plain polisacaride vaccine 23 valent to reduce carriage
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 9 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy children between * 2 to 9 years old. * No history of antibiotic use prior 1 month of enrollment * No history of invasive pneumococcal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage. | 12 months |
Outcome results
None listed